Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Gad Cotter(Momentum Research), Christopher Edwards(Momentum Research), Piotr Ponikowski(Wroclaw Medical University), Beth A. Davison(Inserm), Gerasimos Filippatos(National and Kapodistrian University of Athens), Maria Novosadova(Momentum Research), Karen Sliwa(University of Cape Town), Jelena Čelutkienė(Vilnius University), Marco Metra(Vita-Salute San Raffaele University), Peter S. Pang, Ovidiu Chioncel(Carol Davila University of Medicine and Pharmacy), Étienne Gayat(Inserm), Adriaan A. Voors(University Medical Center Groningen), Alain Cohen‐Solal(Inserm), Albertino Damasceno(Eduardo Mondlane University), Koji Takagi(Momentum Research), Hadiza Saidu(Bayero University Kano), Rafael Díaz(Estudios Clínicos Latinoamérica)
Cited by 1,021
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k